abemaciclib

December 14, 2015December 14, 2015

Lilly and Merck Collaborate to Evaluate Abemaciclib and Keytruda Combo in Phase 1 Clinical Trial

News

Eli Lilly and Merck announced a new immuno-oncology partnership in which they will initiate a Phase 1 study across multiple tumor types to evaluate Lilly’s cyclin-dependent kinase (CDK) 4 & 6 inhibitor abemaciclib ... Read more

October 23, 2015October 23, 2015

AstraZeneca, Lilly Expand Partnership to Explore Drug Combinations for Solid Tumors

News

Partners Eli Lilly and Company and AstraZeneca recently announced they will be extending their current immuno-oncology agreement to develop new combination treatments for solid tumors. According to the amended agreement, the two ... Read more